Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  New Zealand Stock Exchange  >  AFT Pharmaceuticals Limited    AFT   NZAFTE0001S4

AFT PHARMACEUTICALS LIMITED

(AFT)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Aft Pharmaceuticals : Posts Decline in Profit, Rise in Revenue for Six Months Ended September; Shares Down 5%

11/18/2020 | 06:43pm EDT


© MT Newswires 2020
All news about AFT PHARMACEUTICALS LIMITED
04/13SHINTR : AFT: D&O Ongoing Disclosure - Louise ClaytonOpens in a new Window
PU
04/13SHINTR : AFT: D&O Ongoing Disclosure - Malcolm TubbOpens in a new Window
PU
04/13SECISSUE : AFT: Capital Change Notice - Issue of ordinary sharesOpens in a new W..
PU
04/12AFT Pharma's Hand Sanitizer Set for Distribution in Middle East, Africa
MT
04/11AFT PHARMACEUTICALS  : Crystawash Extend distribution in UAE, Kuwait, Oman and K..
PU
04/06AFT PHARMACEUTICALS  : Partners With Poland's Mercapharm and Greece's Vianex for..
MT
04/06GENERAL : AFT: AFT secures new partners in Poland and Greece Opens in a new Wind..
PU
04/01AFT PHARMACEUTICALS  : Lowers Fiscal 2021 Operating Profit Guidance
MT
04/01AFT PHARMACEUTICALS  : Lowers Earnings Guidance for Fiscal 2021 Due to Licensing..
MT
03/31GENERAL : AFT: AFT updates earnings guidanceOpens in a new Window
PU
More news
Financials
Sales 2021 110 M 78,8 M 78,8 M
Net income 2021 7,79 M 5,57 M 5,57 M
Net Debt 2021 31,8 M 22,7 M 22,7 M
P/E ratio 2021 57,0x
Yield 2021 -
Capitalization 444 M 317 M 317 M
EV / Sales 2021 4,31x
EV / Sales 2022 3,58x
Nbr of Employees 86
Free-Float 28,2%
Chart AFT PHARMACEUTICALS LIMITED
Duration : Period :
AFT Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AFT PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 4,61 NZD
Last Close Price 4,24 NZD
Spread / Highest target 15,6%
Spread / Average Target 8,61%
Spread / Lowest Target 1,65%
EPS Revisions
Managers and Directors
NameTitle
Hartley Atkinson Chief Executive Officer, MD & Executive Director
Malcolm Tubby Chief Financial Officer & Secretary
David Mark Flacks Chairman
Douglas John Wilson Independent Non-Executive Director
Jon Lamb Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
AFT PHARMACEUTICALS LIMITED-23.05%316
JOHNSON & JOHNSON1.33%419 864
ROCHE HOLDING AG-0.95%285 584
PFIZER INC.0.43%207 285
NOVARTIS AG-4.61%195 170
MERCK & CO., INC.-6.56%193 467